Condition (MeSH)
von Willebrand Disease, Type 3
ClinicalTrials.gov lists 8 trials for von Willebrand Disease, Type 3 or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
8 of the 8 trials are tagged with von Willebrand Disease, Type 3 itself; the rest are tagged with a narrower condition beneath it.
When did von Willebrand Disease, Type 3 trials start? (6)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 3
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 3 |
| 2024 | 1 |
| 2022 | 1 |
| 2021 | 1 |
| 2018 | 1 |
| 2012 | 1 |
No forecast is made for this condition: it averages 1.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are von Willebrand Disease, Type 3 trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 1/2 | 1 |
| Phase 3 | 1 |
| Observational | 5 |
How many von Willebrand Disease, Type 3 trials are recruiting? (3)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 5 |
| Active, not recruiting | 2 |
| Completed | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most von Willebrand Disease, Type 3 trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Hemab ApS | 2 |
| Hoffmann-La Roche | 2 |
Which serious adverse events do von Willebrand Disease, Type 3 trials report? (5)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Anaemia | 1 | 1 |
| Gastro-Intestinal bleeding | 1 | 1 |
| Headache righr hemisphere | 1 | 1 |
| Intracranial bleeding | 1 | 1 |
| Post-partum bleeding in uterus | 1 | 1 |
Which publications cover von Willebrand Disease, Type 3? (8)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| An evaluation of von Willebrand factor (recombinant) therapy for adult patients living with severe type 3 von Willebrand disease. | Expert review of hematology | 2023 | Yes |
| Longitudinal bleeding assessment in von Willebrand disease utilizing an interim bleeding score. | Journal of thrombosis and haemostasis : JTH | 2022 | Yes |
| Is gingival bleeding a symptom of type 2 and 3 von Willebrand disease? | PloS one | 2018 | Yes |
| Liver transplantation in hemophilia A and von Willebrand disease type 3: perioperative management and post-transplant outcome. | Revista espanola de enfermedades digestivas | 2018 | Yes |
| Prophylaxis in von Willebrand Disease: Coming of Age? | Seminars in thrombosis and hemostasis | 2016 | Yes |
Showing 5 of 8 publications.
Prevalence (39)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Von Willebrand disease type 3 | Point prevalence | <1 / 1 000 000 | United Kingdom | GB | Exact |
| Von Willebrand disease type 3 | Point prevalence | <1 / 1 000 000 | United Kingdom | GB | Exact |
| Von Willebrand disease type 3 | Point prevalence | <1 / 1 000 000 | United Kingdom | GB | Unspecified |
| Von Willebrand disease type 3 | Point prevalence | <1 / 1 000 000 | Austria | Not stated | Exact |
| Von Willebrand disease type 3 | Point prevalence | <1 / 1 000 000 | Italy | Not stated | Exact |
Showing 5 of 39 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Von Willebrand disease type 3 | 166096 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Von Willebrand disease type 3 | 166096 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.